Table 1.

Clinical and laboratory characteristics of COVID-19 and malaria patients.

		COVID-19	Malaria
Patients n		20	10
Age in years (range)		54.55 (33–77)	55.5 (36–71)
Sex
Female		5 (25%)	1 (10%)
Male		15 (75%)	9 (90%)
Comorbidities
None		6 (30%)	5 (50%)
Hypertension		6 (30%)	3 (30%)
Diabetes		3 (15%)	2 (20%)
Coronary heart disease		3 (15%)	0 (0%)
Lung disease		5 (25%)	0 (0%)
Cancer		1 (5%)	1 (10%)
Other		10 (50%)	2 (20%)
Days since start of symptoms (range)		9.65 (4–14)	9.6 (2–21)
Hospitalization days (range)		9.9 (1–33)	4.8 (2–15)
Oxygen therapy needed		10 (50%)	0 (0%)
Lung infiltrates		14 (70%)	0 (0%)
Admission to intensive care unit		3 (15%)	1 (10%)
Disease severity status
Mild		6 (25%)	0 (0%)
Moderate		9 (55%)	8 (80%)
Severe		5 (20%)	2 (20%)
Blood count
White blood cell count	3.8–11.0 Mrd/l	5.54 ± 2,24	5.0 ± 0.96
Lymphocyte count	1,000–3,600/μl	1,055.9 ± 456.4
Hemoglobin	14.0–17.5 g/dl	13.0 ± 1.4	11.83 ± 1.3
Platelets	150–400 Mrd/l	231.75 ± 88.5	108.5 ± 34.1
T lymphocytes
Count	900–2,900/μl	721.2 ± 255.8	n.a.
Percentage	55–84%	67.5 ± 10.7	n.a.
CD4	500–1,350/μl	405.7 ± 151.9	n.a.
CD4%	31–60%	38.4 ± 8.2	n.a.
CD8	290–930/μl	271.1 ± 146.6	n.a.
CD8 %	13–41%	24.7 ± 10.2	n.a.
CD4/CD8 Ratio	0.6–3.6	1.9 ± 0.9	n.a.
Tregs	5.7–10.1%	7.5 ± 3.7	n.a.
Clinical chemistry
CRP	−5 mg/l	74.15 ± 71.2	121.9 ± 65.4
IL-6	<7.0 ng/l	63.02 ± 82.0	n.a.
Ferritin	22.0–322.0 μg/l	740 ± 739	n.a.
Procalcitonin	−0.5 μg/l	0.06 ± 0.06	n.a.
D-dimer	0.21–0.52 mg/l	1.04 ± 0.8	n.a.
Initial Parasitemia %		n.a.	1.995 (1–18)

Data are expressed as absolute numbers n (n/N) or n (range) or mean with standard deviation.